Source comparison
Thymosin Alpha-1 for Chronic Infection Research: Dosing and Protocol Comparison
Chronic Hepatitis B 1.6mg subcutaneous Twice weekly 24–48 weeks IL-2 and IFN-gamma production, HBV-specific CD8+ T-cell frequency Demonstrates reproducible immune reconstitution. Most robust evidence base for Tα1 in infectious disease research Chronic Hepatiti
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B
- 1.6mg subcutaneous
- Twice weekly
- 24–48 weeks
- IL-2 and IFN-gamma production, HBV-specific CD8+ T-cell frequency
- Demonstrates reproducible immune reconstitution. Most robust evidence base for Tα1 in infectious disease research
- Chronic Hepatitis C (pre-DAA era)
- 24 weeks (with interferon)
- TH1 cytokine profile, sustained virologic response
- Mechanistically instructive but clinically superseded by DAAs. Useful for understanding dendritic cell priming
- HIV immune non-responders
- 24 weeks
- CD4+ count increase, IL-2 response to recall antigens
- Pilot-stage evidence. Functional immune recovery matters more than CD4+ count alone
- Tuberculosis (adjuvant)
- 8–12 weeks (with standard antibiotics)
- Time to sputum culture conversion, IFN-gamma production
- Accelerates bacterial clearance. Effect size meaningful in MDR-TB contexts
- Fungal infections (invasive aspergillosis)
- 12 weeks
- Neutrophil and monocyte oxidative burst, galactomannan clearance
- Limited studies. Neutrophil function restoration suggests potential in neutropenic patients